Maya Yasukawa
YOU?
Author Swipe
View article: PARP Inhibitors in Ovarian Cancer: Resistance Mechanisms, Clinical Evidence, and Evolving Strategies
PARP Inhibitors in Ovarian Cancer: Resistance Mechanisms, Clinical Evidence, and Evolving Strategies Open
The introduction of poly (ADP-ribose) polymerase inhibitors (PARPi) into the management of ovarian cancer has transformed the treatment landscape for patients affected by this malignancy. However, as the use of PARPi expands into both fron…
View article: Prevalence of viral DNA in high-grade serous epithelial ovarian cancer and correlation with clinical outcomes
Prevalence of viral DNA in high-grade serous epithelial ovarian cancer and correlation with clinical outcomes Open
Introduction Currently 11 infectious agents are classified as carcinogenic but the role of infectious agents on outcomes of epithelial ovarian cancer is largely unknown. Objective To explore the association between infectious agents and ov…
View article: Feasibility and safety of planned early discharge following laparotomy in gynecologic oncology with enhanced recovery protocol including opioid-sparing anesthesia
Feasibility and safety of planned early discharge following laparotomy in gynecologic oncology with enhanced recovery protocol including opioid-sparing anesthesia Open
Objective This study aims to evaluate the feasibility and safety of planned postoperative day 1 discharge (PPOD1) among patients who undergo laparotomy (XL) in the department of gynecology oncology utilizing a modified enhanced recovery af…
View article: Outcomes of incidentally detected ovarian cancers diagnosed at time of risk-reducing salpingo-oophorectomy in BRCA mutation carriers
Outcomes of incidentally detected ovarian cancers diagnosed at time of risk-reducing salpingo-oophorectomy in BRCA mutation carriers Open
View article: Long-term outcomes after cytoreductive surgery and HIPEC for morcellated uterine leiomyosarcoma; A case series
Long-term outcomes after cytoreductive surgery and HIPEC for morcellated uterine leiomyosarcoma; A case series Open
View article: 544: External validation of the vaginal birth after cesarean delivery calculator
544: External validation of the vaginal birth after cesarean delivery calculator Open
View article: ADAMTS16 mutations sensitize ovarian cancer cells to platinum-based chemotherapy
ADAMTS16 mutations sensitize ovarian cancer cells to platinum-based chemotherapy Open
Ovarian cancer is one of the most lethal malignant tumors in women. The prognosis of ovarian cancer patients depends, in part, on their response to platinum-based chemotherapy. Our recent analysis of genomics and clinical data from the Can…
View article: Association of Somatic Mutations of<i>ADAMTS</i>Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma
Association of Somatic Mutations of<i>ADAMTS</i>Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma Open
ADAMTS mutations may contribute to outcomes in ovarian cancer cases without BRCA1 or BRCA2 mutations and may have important clinical implications.